Naloxon Orpha (Naloxone Hydrochloride)

Naloxone works by competitively binding to mu, kappa and delta opioid receptors in the central nervous system. By displacing opioid agonists without activating the receptors, it blocks their depressant effects, quickly restoring respiratory drive and alertness in individuals who have taken an opioid overdose.

The specific dose of Naloxon Orpha is determined by the prescribing clinician based on the patient’s condition, age, weight and the severity of the opioid exposure. Healthcare professionals follow established clinical guidelines and adjust the dose as needed during emergency treatment.

Limited clinical data are available on naloxone use in pregnancy and lactation. The medication should be used only if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will weigh the urgency of reversing an overdose against the lack of extensive safety data.

To order Naloxon Orpha, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Naloxon Orpha (naloxone) is the most widely used opioid antagonist because of its rapid onset and short duration of action, making it ideal for emergency reversal. Alternatives such as nalmefene have a longer half‑life but a slower onset, which may be less suitable for acute overdose situations.

Naloxon Orpha should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures. Inspect the vial for particulate matter or discoloration before use, and discard any preparation that appears compromised.

Naloxon Orpha is supplied as an injectable solution for intramuscular or intravenous administration. In emergency settings, a typical initial dose is injected into a large muscle (e.g., thigh) or given intravenously, with additional doses administered if respiratory depression persists, according to clinical judgment.

Serious risks include the potential for acute opioid withdrawal, which can cause hypertension, tachycardia, agitation, or seizures, especially in patients dependent on opioids. Rare but life‑threatening reactions such as pulmonary edema or anaphylaxis may also occur and require immediate medical attention.

Naloxon Orpha is contraindicated in individuals with a known hypersensitivity to naloxone or any of the formulation excipients. Caution is advised for patients with severe cardiovascular disease, as rapid reversal of opioid effects can precipitate marked increases in blood pressure and heart rate.